FDA warns EyeTech One that its EYELIVIO lubricant eye ointment is an unapproved new drug and misbranded.
What happened
On September 26, 2024, FDA reviewed EyeTech One's product labeling, website (www.eyelivio.com), and Instagram page for EYELIVIO lubricant eye ointment. FDA found the product is an unapproved new drug because it does not meet the OTC monograph for ophthalmic drug products and has no approved application. FDA also found the product misbranded under the FD&C Act.
What FDA found
The product is an unapproved new drug because it has no FDA-approved application and is not generally recognized as safe and effective for its labeled use.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The product does not meet the OTC monograph M018 because it uses Aloe vera, Arnica montana, and Calendula officinalis as active ingredients, which are not permitted for ophthalmic emollient drug products.
OTC Monograph M018.14The label does not state the amounts of the permitted active ingredients mineral oil and white petrolatum.
OTC Monograph M018.14(b)The website claims the product protects the eyes and ocular surface and provides anti-inflammatory benefits, which go beyond the indications allowed in the OTC monograph.
OTC Monograph M018.65(b)The product is misbranded because it is a nonprescription drug subject to section 505G but does not comply with that section and has no approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)
What FDA wants
FDA asks EyeTech One to notify it in writing within 15 working days of the specific steps taken to correct the violations and prevent recurrence. If the company believes the product is not in violation, it must include its reasoning and supporting information.
Who should pay attention
- brands that sell OTC eye products
- companies that market drugs online or via social media
- regulatory teams managing OTC monograph compliance
This is a summary. Read the original letter on fda.gov.